(28 days)
The ToxiSeal™ Vial Adaptor with External Flip Balloon mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The device also prevents the introduction of microbial contaminations into the drug or fluid path for up to 168 hours (or 7 days) when used as intended.
The ToxiSeal™ Vial Adaptor with External Flip Balloon devices are single-use, sterile, nonpyrogenic CSTD drug vial adaptors that are fitted to the drug vials and are sealed against the closures of the vials. They are used as sterile interfaces between the drug vials and the ProSeal™ Injector or the ProSeal™ Injector Plus (both are syringe adaptors) for the injection of diluents into the drug vials and/or withdrawal of liquids from the vials. In addition, the ToxiSeal™ Vial Adaptor with External Flip Balloon devices equalize the pressure difference which occurs when fluid or air is added to or removed from the drug vial. This neutral pressure is maintained utilizing an external balloon/ expansion chamber.
This is a 510(k) summary for a medical device called "ToxiSeal™ Vial Adaptor with External Flip Balloon". This submission seeks to demonstrate that the new device, which has some material and design changes compared to a previously cleared predicate device, is substantially equivalent and does not require a new premarket approval application.
Here's an analysis of the provided information concerning acceptance criteria and supporting studies, formatted as requested:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly present a table of acceptance criteria with corresponding performance results in a comparative format for each specific criterion. Instead, it lists the standards and types of tests performed, implying that the device met the requirements of these standards. The "Reported Device Performance" in this context refers to the affirmation that testing was conducted and demonstrated conformance with the cited standards and previously cleared devices' performance.
| Acceptance Criterion (Standard or Test Type) | Reported Device Performance |
|---|---|
| Fragmentation study to ISO 22413 & ISO 8871-5 | Performed on the Subject device; met criteria (implied) |
| Vial Adaptor penetration force testing to ISO 22413 | Performed on the Subject device; met criteria (implied) |
| Tests for leakages to ISO 8536-4:2019, Annex A.3 | Performed on the Subject device; met criteria (implied) |
| Volume of pressure equalization study | Leveraged from K222929; met criteria (implied) |
| Testing to (draft) NIOSH CSTD Test Protocol | Leveraged from K222929; met criteria (implied) |
| Microbial ingress/ microbiological integrity testing | Leveraged from K222929; met criteria (implied) |
| Biocompatibility (Cytotoxicity to ISO 10993-5) | Leveraged from K192075; met criteria (implied) |
| Biocompatibility (Sensitization to ISO 10993-10) | Leveraged from K192075; met criteria (implied) |
| Biocompatibility (Intracutaneous Reactivity to ISO 10993-10) | Leveraged from K192075; met criteria (implied) |
| Biocompatibility (Acute Systemic Toxicity to ISO 10993-11) | Leveraged from K192075; met criteria (implied) |
| Biocompatibility (14-day Subacute/ Subchronic Acute Systemic Toxicity to ISO 10993-11) | Leveraged from K192075; met criteria (implied) |
| Biocompatibility (In-vitro Hemolysis Assessment to ISO 10993-4) | Leveraged from K192075 and K192075/S001; met criteria (implied) |
| Biocompatibility (Material Mediated Pyrogenicity to ISO 10993-11) | Leveraged from K192075; met criteria (implied) |
| Biocompatibility (Chemical Characterization and Toxicological Risk Management to ISO 10993-18 and ISO 10993-17) | Leveraged from K192075/S001; met criteria (implied) |
| Particulate matter testing (USP <788>) | Met the acceptance criteria therein |
| Sterilization (ISO 11135: 2014) | Complies with requirements (implied) |
| Package Integrity Tests (ASTM F1980-16, ASTM F88/F88M-21, ASTM F1929-15, EN 868-5: 2009) | Performed on the proposed device; met criteria (implied) |
| Pyrogen Tests (ANSI/AAMI ST72/ 2019, USP 40 <151>, USP-NF <161>, USP-NF <85>) | Performed; met criteria (implied) |
| Shelf-life validation (ASTM 1980-16) | 3 years (36 months) validated |
2. Sample Sizes Used for the Test Set and Data Provenance
- Sample Sizes: The document does not explicitly state the specific number of units or samples used for each individual test. It mentions that testing was performed "on the Subject device" or "on test samples in their finished form aged to the intention i the Subject device validation lots."
- Data Provenance: The document does not specify the country of origin of the data. The studies are described as "bench performance verifications and validations" and refer to past clearances (K222929, K240433, K192075) for much of the leveraged data, implying these were laboratory-based tests. The submission originates from Singapore.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
This information is not applicable to this type of device submission. The device is a physical medical device (vial adaptor), not an AI/ML-based diagnostic or prognostic tool that would require expert-established ground truth for a test set. The validation relies on technical performance standards and biocompatibility.
4. Adjudication Method for the Test Set
This information is not applicable for the same reasons as point 3.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size
This information is not applicable. This is not an AI/ML-based diagnostic device where reader studies would be relevant.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
This information is not applicable. This is a physical medical device.
7. The Type of Ground Truth Used
The "ground truth" for this device's performance is established by conformance to recognized industry standards (ISO, ASTM, USP, ANSI/AAMI) for mechanical, chemical, biological, and sterility properties. For example:
- Mechanical Integrity: Conformance to ISO 22413, ISO 8536-4.
- Biocompatibility: Conformance to ISO 10993 series.
- Sterility: Conformance to ISO 11135.
- Particulate Matter: Conformance to USP <788>.
- Shelf-life: Conformance to ASTM 1980-16.
8. The Sample Size for the Training Set
This information is not applicable. This is a physical medical device, not an AI/ML system that utilizes a training set.
9. How the Ground Truth for the Training Set Was Established
This information is not applicable for the same reason as point 8.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left, there is a symbol representing the Department of Health & Human Services - USA. To the right of this symbol, there is a blue square with the letters "FDA" in white. Next to the blue square, the words "U.S. FOOD & DRUG ADMINISTRATION" are written in blue.
June 21, 2024
Epic Medical Pte. Ltd. Freddie Lee CEO/MD 105 Cecil Street #20-04, The Octagon Singapore, SG 069534 Singapore
Re: K241476
Trade/Device Name: ToxiSeal™ Vial Adaptor with External Flip Balloon Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular Administration Set Regulatory Class: Class II Product Code: ONB Dated: May 24, 2024 Received: May 24, 2024
Dear Freddie Lee:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
{1}------------------------------------------------
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Persache Bennett
Porsche Bennett For David Wolloscheck, Ph.D. Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K241476
Device Name
ToxiSeal™ Vial Adaptor with External Flip Balloon
Indications for Use (Describe)
The ToxiSeal™ Vial Adaptor with External Flip Balloon mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The device also prevents the introduction of microbial contaminations into the drug or fluid path for up to 168 hours (or 7 days) when used as intended.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
o il
K241476 – 510(k) Summary
I. Submitter
Epic Medical Pte. Ltd. 105 Cecil Street #20-04, The Octagon, Singapore 069534. Phone: +65 9635 2618 / +66 81 761 5292
Contact Person: Mr. Freddie LEE, Chief Executive Officer/ Managing Director Date Prepared: June 20, 2024 Content and Format: Prepared in accordance with 21 CFR 807.92 Type of Submission: Special
II. Subject Device
| 510(k) Number: | K241476 |
|---|---|
| Trade/ Device Name: | ToxiSeal™ Vial Adaptor with External Flip Balloon |
| Common/Usual Name: | Closed Antineoplastic and Hazardous Drug Reconstitution andTransfer Device |
| Regulation Number: | 21 CFR 880.5440 |
| Regulation Name: | Intravascular administration set |
| Regulatory Class: | Class: II |
| Classification Product Code: | ONB |
III. Predicate
| 510(k) Number: | K222929 |
|---|---|
| Trade/ Device Name: | ToxiSeal™ Vial Adaptor with External Balloon |
| Common/Usual Name: | Closed Antineoplastic and Hazardous Drug Reconstitution andTransfer Device |
| Regulation Number: | 21 CFR 880.5440 |
| Regulation Name: | Intravascular administration set |
| Regulatory Class: | Class: II |
| Classification Product Code: | ONB |
{4}------------------------------------------------
IV. Device Description
The purpose of this Special 510(k) Submission is to seek FDA clearance prior to the introduction in the US, of a modified design of a ToxiSeal™ Vial Adaptor - the Subject ToxiSeal™ Vial Adaptor with External Flip Balloon. This device is an addition to the ProSeal™ CSTD system of devices (cleared K240433). The nominated Predicate device is the existing ToxiSeal™ Vial Adaptor with External Balloon (cleared K222929).
The ToxiSeal™ Vial Adaptor with External Flip Balloon devices are single-use, sterile, nonpyrogenic CSTD drug vial adaptors that are fitted to the drug vials and are sealed against the closures of the vials. They are used as sterile interfaces between the drug vials and the ProSeal™ Injector or the ProSeal™ Injector Plus (both are syringe adaptors) for the injection of diluents into the drug vials and/or withdrawal of liquids from the vials.
In addition, the ToxiSeal™ Vial Adaptor with External Flip Balloon devices equalize the pressure difference which occurs when fluid or air is added to or removed from the drug vial. This neutral pressure is maintained utilizing an external balloon/ expansion chamber.
The ToxiSeal™ Vial Adaptor with External Flip Balloon devices, designed to be used with the cleared ProSeal™ Injector or Injector Plus within the ProSeal™ CSTD system (K240433), are variants of CSTD vial adaptor component device offerings to the ProSeal™ CSTD system. The additions enhance the completeness of the portfolio of ProSeal™ CSTD devices system.
Changes proposed in this Special 510(k) Submission are as follow:
- · Change of material of vial spike to polypropylene from Tritan copolyester
- · Non-fluid path changes in retention method to external flip balloon, removal of carbon filter and the positioning of its one-way valve
V. Indications for Use Statement (unchanged)
The ToxiSeal™ Vial Adaptor with External Flip Balloon mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The device also prevents the introduction of microbial contaminations into the drug or fluid path for up to 168 hours (or 7 days) when used as intended.
VI. Comparison of Technological Characteristics
The Subject device and the Predicate device share the following key characteristics:
- . Principles of operation
- Expansion film of External Balloon .
- Sterile barrier packaging .
- . Sterilization process
- Shelf-life
An overview table summarizing the comparison between the key characteristics between the Subject and the Predicate device is provided hereunder.
{5}------------------------------------------------
| Characteristiccompared | Predicate DeviceToxiSeal™ Vial Adaptor with External Balloon(K222929) | Subject DeviceToxiSeal™ Vial Adaptor with External FlipBalloon (K241476) | Comment/Discussion |
|---|---|---|---|
| Indications for Usestatement | "The ToxiSeal™ Vial Adaptor with ExternalBalloon mechanically prohibits environmentalcontaminants from entering the system and theescape of drug or vapor concentrations fromthe system, thereby minimizing individual andenvironmental exposure to drug vapor,aerosols, and spills. The device also preventsthe introduction of microbial contaminationsinto the drug or fluid path for up to 168 hours(or 7 days) when used as intended." | "The ToxiSeal™ Vial Adaptor with ExternalFlip Balloon mechanically prohibitsenvironmental contaminants from entering thesystem and the escape of drug or vaporconcentrations from the system, therebyminimizing individual and environmentalexposure to drug vapor, aerosols, and spills.The device also prevents the introduction ofmicrobial contaminations into the drug or fluidpath for up to 168 hours (or 7 days) when usedas intended." | Same |
| Primary product codeand regulationnumber | ONB21 CFR 880.5440 | ONB21 CFR 880.5440 | Same |
| Intended userpopulation/ intendeduse environment | Adequately trainedhealth care professionalsor pharmacists/ clinical setting | Adequately trainedhealth care professionalsor pharmacists/ clinical setting | Same |
| Intendeddrug type | Parenteral drugs | Parenteral drugs | Same |
| R/Prescription use | R only | R only | Same |
| Characteristiccompared | Predicate DeviceToxiSeal™ Vial Adaptor with External Balloon(K222929) | Subject DeviceToxiSeal™ Vial Adaptor with External FlipBalloon (K241476) | Comment/Discussion |
| System componentdevices | 1. ProSeal™ Injector (model 421010)(K240433)2. ProSeal™ Injector Plus (model 421050)(K240433)3. ProSeal™ Connector (model 422010)(K240433)4. ProSeal™ Injection Site Extended Male LuerLock (K240433)5. ProSeal™ Vial Adaptor (3 models 4200X0,for options of vial neck sizes and pressureequalizations) (K240433)6. ToxiSeal™ Vial Adaptor with ExternalBalloon (K222929)7. ProSeal™ Assembly Fixture (Fixture forProSeal™ Vial Adaptor assembly, model424010) (K240433) | 1. ProSeal™ Injector (model 421010) (K240433)2. ProSeal™ Injector Plus (model 421050)(K240433)3. ProSeal™ Connector (422010) (K240433)4. ProSeal™ Injection Site Extended Male LuerLock (K240433)5. ProSeal™ Vial Adaptor (3 models 4200X0, foroptions of vial neck sizes and pressureequalizations) (K240433)6. ToxiSeal™ Vial Adaptor with External Balloon(K222929)7. ToxiSeal™ Vial Adaptor with External FlipBalloon (K241476) the Subject device )8. ProSeal™ Assembly Fixture (Fixture forProSeal™ Vial Adaptor assembly, model424010) (K240433) | Different,the Subject systemcomponent device(#7 in the column |
| Closed SystemTechnology | Physical barrier to preventall drug massesfrom crossing the system boundary | Physical barrier to preventall drug massesfrom crossing the system boundary | Same |
| Drug vialair pressureequalization | Integratedpressure equalization chamber | Integratedpressure equalization chamber | Same |
| Characteristiccompared | Predicate DeviceToxiSeal™ Vial Adaptor with External Balloon(K222929) | Subject DeviceToxiSeal™ Vial Adaptor with External FlipBalloon (K241476) | Comment/Discussion |
| Interfacebetween systemcomponents | Elastomericresealing double-membrane | Elastomericresealing double-membrane | Same |
| Membrane material | Isoprene rubber (IR) | Isoprene rubber (IR) | Same |
| Intended Injector foruse with the Subjectdevice | ProSeal™ Injector (model 421010)(cleared K192075, K222929, K240171)Male Luer Lock tip | ProSeal™ Injector (model 421010) orProSeal™ Injector Plus (model 421050)(cleared K241071 & K240433)both Male Luer Lock tip | Sameboth the ProSeal™Injector Plus andProSeal™ Injector arecleared devices thatmay be used with theSubject device |
| Vial adaptor spike | Plastic (all 12 models, copolyester) | Plastic (all 6 models, polypropylene) | DifferentSee Comment #1 |
| Characteristiccompared | Predicate DeviceToxiSeal™ Vial Adaptor with External Balloon(K222929) | Subject DeviceToxiSeal™ Vial Adaptor with External FlipBalloon (K241476) | Comment/Discussion |
| Design configurationof External Balloon(non-fluid path) | Retention method of external balloon with 2options of clip-on or sticker features(resulting in 12 REFs/ models) | Non-fluid path changes: retention method toexternal flip balloon, removal of carbon filter andthe positioning of its one-way valve (resulting in6 REFs/ models) | DifferentSee Comment #2 |
| Image: clip-on balloon retainer and sticker on balloon retainer | Image: external flip balloon retainer | ||
| 12 models:clip-on balloon retainer (left picture)and sticker on balloon retainer (right picture) | 6 models:external flip balloon retainer | ||
| Hydrophobic filter(non-fluid path) | Polytetrafluoroethylene (PTFE) | Polytetrafluoroethylene (PTFE) | Same |
| Expansion films(non-fluid path) | Polyethylene terephthalate - Polyethylene(PET/PE) laminateand Polyethylene (PE) | Polyethylene terephthalate - Polyethylene(PET/PE) laminateand Polyethylene (PE) | Same |
| Primarypackage top web | Medical grade paper andmedical plastic film, heat sealed | Medical grade paper andmedical plastic film, heat sealed | Same |
| Sterilization method | Ethylene Oxide, EO, SAL 10-6 | Ethylene Oxide, EO, SAL 10-6 | Same |
| Characteristiccompared | Predicate DeviceToxiSeal™ Vial Adaptor with External Balloon(K222929) | Subject DeviceToxiSeal™ Vial Adaptor with External FlipBalloon (K241476) | Comment/Discussion |
| ValidatedShelf life | 3 years (36 months) | 3 years (36 months) | Same |
| Reuseor single-use | Single-use only | Single-use only | Same |
| Labelingspecifications | Meets the requirementsspecified in 21 CFR 801 | Meets the requirementsspecified in 21 CFR 801 | Same |
{6}------------------------------------------------
{7}------------------------------------------------
{8}------------------------------------------------
{9}------------------------------------------------
Discussion of differences in technological characteristics
Comment #1
The formulation (type, make, grade) manufacturer source of polypropylene, manufacturing, processing, sterilization, and addivives are the same as the polypropylene material included in the cleared ProSeal™ Injection Site (K240433) and the cleared ProSeal"" Comector (K192075). Therefore, biocompatibility was leveraged from K240433 and K192075. In additional bench top performance vertification testing over the shelf life was conducted to ISO 8536-4:2019, ISO 22413:2021, and ISO 8871-5:2016 to demonstrate that the difference in technological characteristic (i.e., material) does not raise different questions of safety and effectiveness.
Comment #2
The differences arising out of the proposed chave been functionally verified to the standards listed in Comment #1, and to the standards listed in section VII.B hereunder, on test samples in their finished form aged to the intention i the Subject device validation lots and these differences were found not to raise any new or safety or effectiveness. Further details are provided in sections VII.A and VII.B hereunder.
{10}------------------------------------------------
Performance Data Supporting Substantial Equivalence VII.
A. Functional Performance
The sterile, single-use, non-pyrogenic flexible IV container devices/ bags described in this Summary were evaluated to be in conformance with the following ISO and FDA recognized standards:
- ISO 8536-2:2010. Infusion equipment for medical use Part 2: Closures for infusion bottles .
- ISO 8536-4:2019, Infusion equipment for medical use Part 4: Infusion sets for single use, ● gravitv feed
- ISO 8871-5:2016, Elastomeric parts for parenterals and for devices for pharmaceutical use ● Part 5: Functional requirements and testing
- . ISO 22413:2021, Transfer sets for pharmaceutical preparations – Requirements and test methods
Bench performance verifications and validations are referred to or were performed on the Subject device as detailed hereunder:
- Fragmentation study to ISO 22413 & ISO 8871-5, performed on the Subject device ●
- Vial Adaptor penetration force testing to ISO 22413, performed on the Subject device
- Tests for leakages to ISO 8536-4:2019, Annex A.3, performed on the Subject device ●
- Volume of pressure equalization study under K222929
- Testing to (draft) NIOSH CSTD Test Protocol on existing devices under K222929 ●
- . Microbial ingress/ microbiological integrity testing on existing devices under K222929
B. Biocompatibility
In accordance with ISO 10993-1: 2018, the Subject device, just like the existing device, is classified as: Externally Communicating Device, Blood Path Indirect, Prolonged Contact (>24hr to 30d). The following testing are referred to, from testing on the existing devices cleared as listed hereunder:
- Cytotoxicity to ISO 10993-5 under K192075 ●
- Sensitization to ISO 10993-10 under K192075 .
- Intracutaneous Reactivity to ISO 10993-10 under K192075 .
- Acute Systemic Toxicity to ISO 10993-11 under K192075
- . 14-day Subacute/ Subchronic Acute Systemic Toxicity to ISO 10993-11 under K192075
- . In-vitro Hemolysis Assessment to ISO 10993-4 under K192075 and K192075/S001
- Material Mediated Pyrogenicity to ISO 10993-11 under K192075 .
- . Chemical Characterization and Toxicological Risk Management to ISO 10993-18 and ISO 10993-17 under K192075/S001
Particulate matter testing was conducted in accordance with USP <788> Particulate Matter in Injections, and found to have met the acceptance criteria therein.
{11}------------------------------------------------
ani t
C. Sterility, Shipping, and Shelf-Life
The Subject device, like the existing device cleared under K222929, complies with sterilization requirements of ISO 11135: 2014, Sterilization of Health Care Products - Ethylene Oxide -Part 1: Requirements for Development, Validation and Routine Control of a Sterilization Process for Medical Devices and the following testing/ evaluations:
- Package Integrity Tests per ASTM F1980-16, Standard guide for accelerated aging of sterile ● barrier systems for medical devices and Sterile Barrier Packaging Testing performed on the proposed device: Seal strength – ASTM F88/F88M-21, Standard test method for seal strength of flexible barrier materials, ASTM F1929-15, Standard test method for detecting seal leaks in porous medical device packaging by dye penetration, EN 868-5: 2009, Packaging materials and systems for medical devices which are to be sterilized – Part 5: Heat and self-sealable pouches and reels of paper and plastic film construction – Requirements and test methods
- Pyrogen Tests per ANSI/AAMI ST72/ 2019, Bacterial endotoxins Test methods, routing . monitoring, and alternatives to batch testing, USP 40 <151>, Pyrogen test (USP rabbit test), USP-NF <161>, Medical Devices-Bacterial Endotoxin and Pyrogen Tests, USP-NF <85>, Bacterial Endotoxins Test
- Shelf-life of 3 years has been validated using the FDA recognized standard, ASTM 1980-16, ● Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices
VIII. Clinical Tests
Not applicable.
IX. Conclusion
The differences between the Predicate and the Subject device do not raise any new or different questions of safety or effectiveness. The Subject ToxiSeal™ Vial Adaptor with External Flip Balloon is substantially equivalent to the Predicate, the ToxiSeal™ Vial Adaptor with External Balloon, with respect to the indications for use, principles of operation and technological characteristics.
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.